Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Type 1 Diabetes TrialNet Resource Report Resource Website 10+ mentions |
Type 1 Diabetes TrialNet (RRID:SCR_001508) | TrialNet | clinical trial, data or information resource, database, disease-related portal, portal, resource, topical portal | International network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. It is conducting clinical trials with researchers from 18 Clinical Centers in the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand. In addition, more than 150 medical centers and physician offices are participating in the TrialNet network. Studies are available for people newly diagnosed with type 1 diabetes, as well as for relatives of people with type 1 diabetes who are at greater risk of developing the disease. This NIH-sponsored clinical trials network conducts studies designed to evaluate new approaches to prevent or ameliorate type 1 diabetes specifically by interdicting the type 1 diabetes disease process. These include interventions designed to decrease beta-cell destruction and/or enhance beta-cell survival. Studies are conducted in non-diabetic persons at risk of type 1 diabetes in an effort to delay the development of type 1 diabetes as a clinical disease; or (if initiated prior to appearance of autoimmunity) in an effort to delay the appearance of autoimmunity; or in individuals with type 1 diabetes who are either newly diagnosed or have evidence of sustained beta cell function. Studies include long-term follow-up of subjects developing type 1 diabetes. The TrialNet network also supports natural history and genetics studies in populations screened for or enrolled in studies conducted by the TrialNet study group. In addition, TrialNet will evaluate methodologies that enhance the conduct of clinical trials interdicting the type 1 diabetes disease process. | intervention, beta-cell, clinical, child, young human, natural history, genetics, prevention, delay |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: University of South Florida; Florida; USA is parent organization of: Living Biobank |
Diabetes, Type 1 diabetes | NIDDK U01DK061058 | Available to the research community | nlx_152812 | SCR_001508 | 2026-09-12 12:55:26 | 22 | ||||||
|
Ancora Resource Report Resource Website 10+ mentions |
Ancora (RRID:SCR_001623) | Ancora | analysis service resource, data analysis service, data or information resource, database, production service resource, service resource | Web resource that provides data and tools for exploring genomic organization of highly conserved noncoding elements (HCNEs) for multiple genomes. It includes a genome browser that shows HCNE locations and features novel HCNE density plots as a powerful tool to discover developmental regulatory genes and distinguish their regulatory elements and domains. They identify HCNEs as non-exonic regions of high similarity between genome sequences from distantly related organisms, such as human and fish, and provide tools for studying the distribution of HCNEs along chromosomes. Major peaks of HCNE density along chromosomes most often coincide with developmental regulatory genes. Their aim with this site is to aid discovery of developmental regulatory genes, their regulatory domains and their fundamental regulatory elements. | genome, highly conserved noncoding element, noncoding element, regulatory gene, regulatory domain, regulatory element, developmental regulatory gene, evolution, enhancer |
is related to: MONARCH Initiative has parent organization: University of Bergen; Bergen; Norway |
Research Council of Norway ; Bergen Research Foundation ; Sars Centre |
PMID:18279518 | Free, Freely available | nlx_153891 | SCR_001623 | Atlas of Noncoding Conserved Regions in Animals | 2026-09-12 12:55:28 | 20 | |||||
|
CKID A Prospective Cohort Study of Kidney Disease in Children Resource Report Resource Website 10+ mentions |
CKID A Prospective Cohort Study of Kidney Disease in Children (RRID:SCR_001500) | CKID | bibliography, data or information resource, disease-related portal, portal, research forum portal, resource, topical portal | Prospective, observational cohort study of children with mild to moderate chronic kidney disease (CKD) to: (1) determine risk factors for progression of pediatric chronic kidney disease (CKD); (2) examine the impact of CKD on neurocognitive development; (3) examine the impact of CKD on risk factors for cardiovascular disease, and; (4) examine the impact of CKD on growth. The CKiD study population will include a cohort of 540 children, age 1 16 years, expected to be enrolled over a 24-month period. | child, young human, pediatric, risk factor, kidney function, neurodevelopment, cognitive ability, behavior, kidney, urologic problem, glomerular disease, adverse effect, cognition, growth, adolescent, infant, clinical |
is listed by: NIDDK Information Network (dkNET) has parent organization: Johns Hopkins University; Maryland; USA |
Chronic kidney disease, Renal disease, Cardiovascular disease | NIDDK U01DK066174; NCRR M01RR000052 |
Free, Freely available | nlx_152790 | SCR_001500 | CKID: A Prospective Cohort Study of Kidney Disease in Children, Chronic Kidney Disease in Children | 2026-09-12 12:55:26 | 10 | |||||
|
Collaborative Islet Transplant Registry Resource Report Resource Website 1+ mentions |
Collaborative Islet Transplant Registry (RRID:SCR_001466) | CITR | data or information resource, data repository, database, narrative resource, report, resource, service resource, storage service resource | Collect, analyze, and communicate on comprehensive and current data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers to expedite progress and promote safety in islet/beta cell transplantation. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community. Annual Reports are available. Islet/beta cell transplantation is a complex procedure with many factors contributing to the outcome. Compiling and analyzing data from all transplant centers in the US, Canada, as well as some European and Australian centers will accelerate the identification of both critical risk factors and key determinants of success and thereby guide transplant centers in developing and refining islet/beta cell transplant protocols. The inclusion of the term collaborative in the name of the Registry emphasizes the importance of collaboration in fulfilling the CITR mission and goals. Close collaboration with the transplant centers will ensure that relevant questions are addressed, that data submitted are accurate and complete, and that the needs of the transplant community are served. Information on how to participate as a CITR Transplant Center and to receive a transplant center application is available through the website. Progress in islet transplantation depends entirely on complete, high-quality medical data, including the information patients consented to report to the Collaborative Islet Transplant Registry. To make it as easy as possible to provide updated information about patient's health, an on-line questionnaire is available or patients can mail it to their transplant center. This information is very important in the continuing search for a cure for Type 1 diabetes. | transplant center, transplant, islet, beta cell, clinical, islet transplantation, beta cell transplantation, outcome, metadata standard, adverse event report, diabetes, data element, bibliography, questionnaire, protocol, risk factor, case report form, allograft, pancreatectomy, autograft, islet processing | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK N01-DK6-2868; NIDDK N01-DK1-2472 |
PMID:15387102 | Free, Freely Available | nlx_152693 | SCR_001466 | 2026-09-12 12:55:26 | 9 | |||||
|
PhenoGen Informatics Resource Report Resource Website 10+ mentions |
PhenoGen Informatics (RRID:SCR_001613) | PhenoGen | analysis service resource, application programming interface, data access protocol, data analysis service, data or information resource, data repository, data set, production service resource, service resource, software resource, source code, storage service resource | Website for analyzing microarray data. Software toolbox for storing, analyzing and integrating microarray data and related genotype and phenotype data. The site is particularly suited for combining QTL and microarray data to search for candidate genes contributing to complex traits. In addition, the site allows, if desired by the investigators, sharing of the data. Investigators can conduct in-silico microarray experiments using their own and/or shared data. There are five major sections of the site: Genome/Transcriptome Data Browser, Microarray Analysis Tools, Gene List Analysis Tools, QTL Tools, and Downloads. The genome/transcriptome data browser combines a genome browser with all the microarray, RNA-Seq, and Genomic Sequencing data. This provides an effective platform to view all of this data side by side. Source code is available on GitHub. | genome, transcription, microarray, gene, quantitative trait loci, analysis, complex trait, genotype, phenotype, high-throughput, rna-seq, snp, genomic marker, region, data sharing, normalize, statistics, gene list, pathway, expression value, expression, correlation, exon, annotation, promoter, homolog, brain, heart, liver, adipose, candidate gene, genetics, transcriptome, eqtl, genome browser, inbred panel |
is related to: MONARCH Initiative has parent organization: University of Colorado Denver; Colorado; USA |
NIAAA R01 AA13162; NIAAA R24 AA013162; NIAAA U01 AA013524 |
PMID:17760997 | Free, Freely available | rid_000093, nlx_153879, r3d100011596 | https://github.com/TabakoffLab/PhenogenCloud, https://doi.org/10.17616/R3WS7F | http://phenogen.ucdenver.edu, http://phenogen.uchsc.edu | SCR_001613 | PhenoGen Informatics - The site for quantitative genetics of the transcriptome. | 2026-09-12 12:55:28 | 22 | |||
|
Teen-Longitudinal Assessment of Bariatric Surgery Resource Report Resource Website |
Teen-Longitudinal Assessment of Bariatric Surgery (RRID:SCR_001492) | consortium, data or information resource, organization portal, portal | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 29,2023. Consortium made up of five clinical centers and a data coordinating center. The goal of Teen-LABS is to conduct clinical, epidemiological, and behavioral research in adolescent bariatric surgery, through an observational prospective study protocol. Teen-LABS is an ancillary study to LABS, an observational study of adult bariatric surgery. Research staff, certified in standardized uniform data collection according to the protocol, collect data at pre-operative research visits, at surgery, 30 days and six months post-operative, and annual post-operative research visits at the five participating centers. | adolescent human, bariatrics, pre-operative, at surgery, post-operative, clinical, epidemiology, behavior, surgical outcome, metadata standard, observational study, clinical, experimental protocol, evidence-based recommendation, patient evaluation, follow-up care | is listed by: NIDDK Information Network (dkNET) | Bariatric surgery, Obesity | NIDDK R01DK080020 | THIS RESOURCE IS NO LONGER IN SERVICE | SCR_014388, nlx_152747 | SCR_001492 | Teen-LABS, Adolescent Bariatrics: Assessing Health Benefits and Risks, Teen-Longitudinal Assessment of Bariatric Surgery, Adolescent Bariatrics: Assessing Health Benefits and Risks (Teen-LABS) | 2026-09-12 12:55:26 | 0 | ||||||
|
BARI 2D Resource Report Resource Website 1+ mentions |
BARI 2D (RRID:SCR_001496) | BARI 2D, BARI-2D | clinical trial | A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care. | clinical, cholesterol, blood pressure, counseling, insulin, epidemiology, longitudinal, stenting, bypass surgery, standard-of-care study, standard-of-care, treatment, medication, outcome, medical cost, blood, urine, biomaterial supply resource |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Type 2 diabetes, Cardiovascular disease, Heart attack, Stroke | NCRR 5M01RR000847-36 | PMID:23757426 PMID:23735723 PMID:23500245 PMID:23067918 PMID:23008442 PMID:22527794 PMID:22496082 PMID:21958742 |
Free, Freely available | nlx_152754 | SCR_001496 | Bypass Angioplasty Revascularization Investigation (BARI) 2 Diabetes, Bypass Angioplasty Revascularization Investigation 2 Diabetes | 2026-09-12 12:55:26 | 1 | ||||
|
Juvenile Diabetes Research Foundation Resource Report Resource Website 50+ mentions |
Juvenile Diabetes Research Foundation (RRID:SCR_001522) | JDRF | institution | Global funder of type 1 diabetes (T1D) research that aims to progressively remove the impact of T1D from people's lives until a world without T1D is achieved. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes. | treatment, prevention, cure, research, education |
is listed by: NIDDK Information Network (dkNET) is affiliated with: Helmsley Cellular Research Hub is related to: JDRF Artificial Pancreas Project Consortium is related to: Kidney Health Initiative |
Type 1 diaberes, Diabetes | Free, Freely available | grid.429307.b, Crossref funder ID: 100008871, nlx_152841, Wikidata: Q6107958, ISNI: 0000 0004 0575 6413 | https://ror.org/00vqxjy61 | SCR_001522 | JDRF International, Juvenile Diabetes Research Foundation International | 2026-09-12 12:55:26 | 66 | |||||
|
Multiple-Path Particle Dosimetry Model Resource Report Resource Website 10+ mentions |
Multiple-Path Particle Dosimetry Model (RRID:SCR_001486) | MPPD | software resource | Computational model that can be used for estimating human and rat airway particle dosimetry. The model is applicable to risk assessment, research, and education. The MPPD model calculates the deposition and clearance of monodisperse and polydisperse aerosols in the respiratory tracts of rats and human adults and children (deposition only) for particles ranging in size from ultrafine (0.01 micrometers) to coarse (20 micrometers). The models are based on single-path and multiple-path methods for tracking air flow and calculating aerosol deposition in the lung. The single-path method calculates deposition in a typical path per airway generation, while the multiple-path method calculates particle deposition in all airways of the lung and provides lobar-specific and airway-specific information. Within each airway, deposition is calculated using theoretically derived efficiencies for deposition by diffusion, sedimentation, and impaction within the airway or airway bifurcation. Filtration of aerosols by the nose and mouth is determined using empirical efficiency functions. The MPPD model includes calculations of particle clearance in the lung following deposition. | model, computational model, particle dosimetry, risk assessment, adult human, child, aerosol, deposition, clearance, lung | is related to: The Hamner Institute for Health Sciences: BMDExpress and The multiple-path particle dosimetry | PMID:8566482 | Free, Freely available | nlx_152744 | http://www.ara.com/products/mppd.htm | SCR_001486 | Multiple Path Particle Dosimetry Model | 2026-09-12 12:55:26 | 15 | |||||
|
Globin Gene Server Resource Report Resource Website 10+ mentions |
Globin Gene Server (RRID:SCR_001480) | Globin Gene Server | analysis service resource, data analysis service, data or information resource, database, narrative resource, production service resource, resource, service resource, software resource, source code, training material | Data and tools for studying the function of DNA sequences, with an emphasis on those involved in the production of hemoglobin. It includes information about naturally-occurring human hemoglobin mutations and their effects, experimental data related to the regulation of the beta-like globin gene cluster, and software tools for comparing sequences with one another to discover regions that are likely to play significant roles. | dna sequence, hemoglobin, mutation, globin gene cluster, sequence comparison, functional genomics, gene, alignment, genetic analysis, variant, gene expression, protein, thalassemia, globin gene, genome, pairwise alignment, multiple alignment, annotation, sequence analysis, dna |
is listed by: NIDDK Information Network (dkNET) has parent organization: Pennsylvania State University |
NLM R01LM05773; NLM R01LM05110; NIDDK DK27635 |
PMID:11857738 PMID:11480780 PMID:9799599 PMID:9576329 PMID:8088828 |
Free, Freely available | nlx_152723 | SCR_001480 | 2026-09-12 12:55:26 | 30 | ||||||
|
Nonalcoholic Steatohepatitis Clinical Research Network Resource Report Resource Website 10+ mentions |
Nonalcoholic Steatohepatitis Clinical Research Network (RRID:SCR_001519) | NASH CRN | clinical trial, data or information resource, disease-related portal, portal, research forum portal, resource, topical portal | Clinical research network to focus on the etiology, contributing factors, natural history, complications, and therapy of nonalcoholic steatohepatitis. They research the nature and underlying cause of Nonalcoholic Steatohepatitis (NASH) and conduct clinical studies on prevention and treatment. Approximately 1,500 pediatric and adult participants throughout the United States and Canada with nonalcoholic fatty liver disease (NAFLD) have enrolled into a database. The NASH CRN has recently reopened the database to enroll additional pediatric and adult participants with NAFLD. Serum, liver tissue, and genomic DNA samples are being collected and stored in the NIDDKrepository for ongoing as well as future studies. A three-arm randomized, placebo-controlled clinical trial of pioglitazone versus vitamin E completed enrollment in 2009. In addition to this adult trial, a similar trial in pediatric NASH patients randomized 180 children to receive treatment with vitamin E, metformin, or placebo. | prevention, treatment, pediatric, child, adult human, serum, liver tissue, dna, placebo, pioglitazone, vitamin e, metformin, etiology, contributing factor, natural history, complication, therapy, young human, database, clinical trial, bibliography, patient registry |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: Johns Hopkins University; Maryland; USA |
Nonalcoholic steatohepatitis, Nonalcoholic fatty liver disease | NIDDK 1ZIADK075013 | Free, Freely available | nlx_152845 | https://www.nashcrn.com | SCR_001519 | Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Clinical Research Network in Nonalcoholic Steatohepatitis | 2026-09-12 12:55:26 | 21 | ||||
|
Jaeb Center for Health Research Resource Report Resource Website 1+ mentions |
Jaeb Center for Health Research (RRID:SCR_001513) | JCHR | institution | Freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research that focus on projects involving eye disorders or type 1 diabetes. | epidemiologic research, epidemiology, clinical, disease, clinical trial, eye |
is parent organization of: Diabetes Research in Children Network is parent organization of: Diabetic Retinopathy Clinical Research Network is parent organization of: JDRF Artificial Pancreas Project Consortium |
Type 1 diabetes, Multiple sclerosis, Eye disorder, Diabetes | Free, Freely available | ISNI: 0000 0004 0586 473X, nlx_152815, grid.414912.b | https://ror.org/04ezjnq35 | SCR_001513 | 2026-09-12 12:55:26 | 5 | ||||||
|
Pediatric Acute Liver Failure Study Resource Report Resource Website |
Pediatric Acute Liver Failure Study (RRID:SCR_001478) | PALF | data or information resource, disease-related portal, portal, research forum portal, resource, topical portal | Study group and network for a 2008 longitudinal study for the etiology, diagnosis, treatment, and outcome of acute liver failure in infants, children, and adolescents. Data from patients include urine, bile, serum, liver tissue, cell lines derived from fibroblast culture, and DNA. | management strategy, infant, child, adolescent, clinical, liver, patient care, rare disease, blood, tissue, longitudinal, urine, bile, serum, liver tissue, cell line, fibroblast culture, dna, etiology, diagnosis, treatment, outcome |
is listed by: NIDDK Information Network (dkNET) is related to: Acute Liver Failure Study Group has parent organization: University of Pittsburgh; Pennsylvania; USA |
Acute liver failure | NIDDK U01DK072146 | Free, Freely available | nlx_152715 | http://www.palfstudy.org/ | SCR_001478 | Pediatric Acute Liver Failure (PALF) Study, Pediatric Acute Liver Failure (PALF) Study Group | 2026-09-12 12:55:26 | 0 | ||||
|
TRIGR Resource Report Resource Website 1+ mentions |
TRIGR (RRID:SCR_001550) | TRIGR | clinical trial | International, randomized, double-blinded trial to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants. 2160 eligible infants were randomized to test or control formulas when mothers decide to wean from exclusive breastfeeding. The participants will be monitored up to the age of 10 years for the appearance of diabetes-predictive autoantibodies and clinical type 1 diabetes. The TRIGR trial will determine whether delayed exposure to intact food proteins will reduce the chances of developing type 1 diabetes later in life. All babies in the study received the recommendation to breastfeed for at least the first six months of life. If a mother was unable to exclusively breastfeed before the baby was 8 months of age, her child was randomly assigned to one of two groups. One group of these babies received a trial formula based on extensively hydrolyzed protein; the other group received another trial formula containing a smaller amount of hydrolyzed protein. In the hydrolyzed formula, the big protein molecules have been split into very small fragments to provide a source of nutritional amino acids, but the fragments are likely too small to stimulate the immune system. The TRIGR trial will also be able to analyze whether exclusive breastfeeding per se can reduce the risk of the children to develop type 1 diabetes. | casein hydrolysate formula, newborn, hydrolyzed infant formula, genetically susceptible, insulin, cow's milk, infant, feeding, diet, intervention, genetic risk, bibliography, dietary intervention, wean, prevention, nutrition, nonhydrolyzed infant formula, breast feeding, infant formula |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of South Florida; Florida; USA |
Type 1 diabetes, Diabetes | NICHD HD040364; NICHD HD042444; NICHD HD051997; RTD programme Quality of Life and Management of Living Resources contract QLK1-2002-00372 |
PMID:21153533 PMID:17550422 |
Free, Freely available | nlx_152860 | http://trigr.epi.usf.edu/, http://clinicaltrials.gov/show/NCT00179777 | SCR_001550 | TRIGR - Trial to Reduce IDDM in the Genetically at Risk, Trial to Reduce IDDM in the Genetically at Risk, TRIGR trial | 2026-09-12 12:55:27 | 1 | |||
|
TOMUS Resource Report Resource Website |
TOMUS (RRID:SCR_001549) | TOMUS | bibliography, clinical trial, data or information resource, resource | Study that compared the outcomes of two minimally invasive surgical procedures to treat stress urinary incontinence in women. These procedures are called mid-urethral slings. The procedures insert a mesh sling or hammock to support the bladder neck so that urine does not leak. Both procedures have been approved by the FDA and have been shown to be safe and successful in treating stress urinary incontinence. However, it is not known if one is better than the other. This study answers that question. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and the need for other treatments(s) after surgery. Follow-up will be a minimum of two years. Stress urinary incontinence is the accidental leakage of urine during activities such as coughing, laughing, sneezing, or lifting heavy objects. | surgical procedure, female, mid-urethral sling, treatment, outcome, quality of life, sexual function, complication, retropubic mid-urethral sling, transobturator mid-urethral sling, adult human |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: Urinary Incontinence Treatment Network |
Stress urinary incontinence, Urinary incontinence | NIDDK U01DK060401; NIDDK U01DK060379; NIDDK U01DK060397; NIDDK U01DK058234; NIDDK U01DK060393; NIDDK U01DK058229; NIDDK U01DK058225 |
PMID:20479459 PMID:22378483 PMID:21422865 PMID:21925636 PMID:23635737 |
Free, Freely available | nlx_152859 | SCR_001549 | Trial Of Mid-Urethral Slings, TOMUS-Trial Of Mid-Urethral Slings | 2026-09-12 12:55:27 | 0 | ||||
|
SISTEr Resource Report Resource Website 100+ mentions |
SISTEr (RRID:SCR_001542) | SISTEr | clinical trial, data or information resource, data set, resource | Clinical trial under the Urinary Incontinence Treatment Network to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s) after surgery. Follow-up will be a minimum of two years and up to four years. | urinary, incontinence, dataset, surgical procedure, outcome, quality of life, sexual function, satisfaction, treatment, complication, burch procedure, sling procedure, female, surgery |
is listed by: NIDDK Information Network (dkNET) has parent organization: Urinary Incontinence Treatment Network |
Urinary incontinence, Stress, Stress urinary incontinence | NIDDK ; NICHD |
Free, Freely available | nlx_152852 | http://www.uitn.net/sister.asp | SCR_001542 | Stress Incontinence Surgical Treatment Efficacy Trial | 2026-09-12 12:55:27 | 151 | ||||
|
Immune Tolerance Network (ITN) Resource Report Resource Website 10+ mentions |
Immune Tolerance Network (ITN) (RRID:SCR_001535) | ITN | clinical trial, data or information resource, funding resource, portal, topical portal | International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington. | immune tolerance, prevent, cure, disease, multiple sclerosis, therapy, biomarker, transplant |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources is related to: Immune Tolerance Network TrialShare has parent organization: Benaroya Research Institute |
Type 1 diabetes, Diabetes, Allergy, Asthma, Autoimmune disease, Transplantation, Immunological disorder | NIAID N01AI15416 | nlx_152838 | SCR_001535 | 2026-09-12 12:55:27 | 15 | |||||||
|
HALT-C Trial Resource Report Resource Website |
HALT-C Trial (RRID:SCR_001534) | HALT-C Trial, HALT-C | bibliography, clinical trial, data or information resource, resource | Multi-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patient enrollment began in 2000 and was completed in 2003 at 10 clinical centers, which were supported by a data coordinating center, virological testing center, and central sample repository. Patients with chronic hepatitis C and advanced fibrosis or cirrhosis on liver biopsy who failed to respond to a previous course of interferon alfa were enrolled in this study. Patients were initially treated with a 24-week course of peginterferon alfa-2a and ribavirin. Patients who remained hepatitis C virus RNA positive were then randomized to receive maintenance, low-dose peginterferon or to be followed on no treatment. Liver biopsies were done before enrollment and after 2 and 4 years of treatment or follow-up. The endpoints were development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, death, or liver transplantation. 1050 patients were randomized and followed through the 4 year randomized phase of the trial and as long as 4 years off treatment. Serum samples collected at multiple time points, DNA and liver tissue are available for scientific investigation. | interferon, progression, cirrhosis, prevention, liver cancer, liver transplantation, liver, pegylated interferon, clinical, outcome, adult human, dna, liver tissue, serum, blood, b lymphoblastoid cell-line, epstein-barr virus infection in peripheral blood mononuclear cell, peripheral blood mononuclear cell, biomaterial supply resource, formalin fixed, histology, frozen, stained liver slide, unstained liver slide, advanced fibrosis, liver biopsy, peginterferon alfa-2a, ribavirin |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Central Repository is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) |
Hepatitis C virus, Chronic hepatitis C | NIDDK | Free, Freely available | nlx_152835 | http://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm | http://www.haltctrial.org/ | SCR_001534 | Hepatitis C Antiviral Long-term Treatment against Cirrhosis, Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial, Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial | 2026-09-12 12:55:27 | 0 | |||
|
TaLasso Resource Report Resource Website 1+ mentions |
TaLasso (RRID:SCR_001726) | TaLasso | analysis service resource, data analysis service, production service resource, service resource, software resource | Tool for quantification of human miRNA-mRNA Interactions. TaLasso is also available as Matlab or R code. | mirna, mrna, matlab, r, gene expression, gene |
is listed by: OMICtools has parent organization: Autonomous University of Madrid; Madrid; Spain |
PMID:22348024 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_00417 | SCR_001726 | 2026-09-12 12:55:30 | 1 | |||||||
|
DTI and Fibertools Software Package Resource Report Resource Website 1+ mentions |
DTI and Fibertools Software Package (RRID:SCR_001641) | DTI and Fibertools, DTI&FiberTools | data processing software, image processing software, software application, software resource, software toolkit | Implemented under MATLAB, this DTI image processing toolbox provides import-filters for several MR file standards, a processing unit to calculate the diffusion tensors; several GUI based tools to calculate fiber tracks and to evaluate the DTI dataset. The results can be filed as images with 3D impression or can be logged in formatted ASCII files. Tools and features: * DTI Processing Unit: Calculates the diffusion tensors and their eigenvalues and eigenvectors. Different file formats are supported (like DICOM, Bruker, binary files, Matlab structures). The standard SIEMENS and GE diffusion encoding schemes are supported; other schemes have to be defined in a separate text, .m or .mat file. * FiberTracking: ** Fiber tracking is realized by using the FACT algorithm (Mori et al., Annal. Neurol 1999). ** Probabilistic tracking realized by using the PiCo (Parker et al., JMRI 2003) approach but with DTI data as basis. It is possible to extract pathways between two seeds by combining two maps (Kreher et al., NeuroImage 2008). ** Global Fiber Tracking on basis of HARDI or DTI data. The method is based on the approach reported in (Marco Reisert et al: Global fiber reconstruction becomes practical. NeuroImage 54(2):955-62) * FiberViewer: ** Visualization and Navigation through different data modalities like DTI maps, fiber tracks, diffusion main directions. ** Supports different kinds of DTI maps (e.g. FA, Trace, lambda images ) ** Creation and manipulation of mask based ROIs. ** Selection of streamline fibers ** Visualization of probabilistic fiber tracking results ** Documentation by logging statistics of ROIs and fiber tracks into text files. ** Import/Export from/to ANALYZE or Nifti * 3D Visualizer: Visualization of map slices, ROIs, and fiber tracks with 3D impression. * Batch Editor: Automatic processing of high amounts of data. Possibility to link processing with SPM8 easily. | diffusion, dti, fiber tracking, diffusion tensor, visualization, navigation |
is related to: Diffusion MRI of Traumatic Brain Injury has parent organization: University of Freiburg; Baden-Wurttemberg; Germany |
Free, Available for download, Freely available | nlx_153913 | SCR_001641 | DTI & Fibertools | 2026-09-12 12:55:28 | 5 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.